Skip to Content
Merck
CN

16374

4-Bromobenzenesulfonamide

≥99.0% (T)

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C6H6BrNO2S
CAS Number:
Molecular Weight:
236.09
UNSPSC Code:
12352100
NACRES:
NA.22
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
2691657
Assay:
≥99.0% (T)
Form:
solid
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


assay

≥99.0% (T)

form

solid

functional group

bromo

SMILES string

NS(=O)(=O)c1ccc(Br)cc1

InChI

1S/C6H6BrNO2S/c7-5-1-3-6(4-2-5)11(8,9)10/h1-4H,(H2,8,9,10)

InChI key

STYQHICBPYRHQK-UHFFFAOYSA-N

General description

4-Bromobenzenesulfonamide is a metabolite of ebrotidine, a new H2-receptor antagonist.

Application

4-Bromobenzenesulfonamide was used as reagent in preparation of cobalt(III) complexes of N,R-sulfonyldithiocarbimate anion. It was also used in the synthesis of 2-, 3- and 4-(substituted-phenylethynyl)benzenesulfonamides.


pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



E Rozman et al.
Journal of pharmaceutical sciences, 83(2), 252-254 (1994-02-01)
Ebrotidine is a new H2-receptor antagonist which exhibits a remarkable ability for gastric mucosal protection. A preliminary metabolic pathway for this compound was proposed and the hypothetic metabolites were synthesized. The presence of ebrotidine and its metabolites ebrotidine S-oxide and
Gloria Uccello-Barretta et al.
Bioorganic & medicinal chemistry, 12(2), 447-458 (2004-01-16)
NMR spectroscopic and molecular modelling methods have been employed to describe the complexation of trans-N-4-[N'-(4-chlorobenzoyl)hydrazinocarbonyl]cyclohexylmethyl-4-bromobenzenesulfonamide, a new chemotype of NPY-5 antagonist, and beta-cyclodextrin, revealing the coexistence of two different kinds of 1:1 complexes where conformational changes of the guest compound
Raymond Anana et al.
Bioorganic & medicinal chemistry, 14(15), 5259-5265 (2006-04-26)
A group of regioisomeric phenylethynylbenzenesulfonamides possessing a COX-2 SO2NH2 pharmacophore at the para-, meta- or ortho-position of the C-1 phenyl ring, in conjunction with a C-2 substituted-phenyl (H, OMe, OH, Me, F) group, were synthesized and evaluated as inhibitors of



Global Trade Item Number

SKUGTIN
16374-5G04061838747761
16374-100G04061838747754